# EDGAR Filing Document

**Accession Number:** 0000078003
**File Stem:** 0000078003-23-000061
**Filing Date:** 2023-3
**Character Count:** 3985
**Document Hash:** fee7f57f714aed8620a0b55b032458a9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000078003-23-000061.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0000078003-23-000061

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PFIZER INC
- **CENTRAL INDEX KEY:** 0000078003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 135315170
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-03619
- **FILM NUMBER:** 23781940

**BUSINESS ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192
- **BUSINESS PHONE:** 2127332323

**MAIL ADDRESS:**
- **STREET 1:** 66 HUDSON BOULEVARD EAST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001-2192

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PFIZER CHARLES & CO INC
- **DATE OF NAME CHANGE:** 19710908

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ⌧ Filed by a Party Other Than the Registrant ◻

Check the Appropriate Box:

---

| | |
|:---|:---|
| ◻ | Preliminary Proxy Statement |
| ◻ | **Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))** |
| ◻ | Definitive Proxy Statement |
| ⌧ | Definitive Additional Materials |
| ◻ | Soliciting Material Pursuant to §240.14a-12 |
| **Pfizer Inc.** | **Pfizer Inc.** |
| **(Name of Registrant as Specified In Its Charter)** | **(Name of Registrant as Specified In Its Charter)** |
| **(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** | **(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** |
| Payment of filing fee (Check all boxes that apply): | Payment of filing fee (Check all boxes that apply): |
| ⌧ | No fee required |
| ◻ | Fee paid previously with preliminary materials |
| ◻ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

---

------

![](votereminder2023001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Margaret M. Madden 66 Hudson Boulevard East New York, NY 10001 YOUR VOTE IS IMPORTANT - PLEASE VOTE YOUR SHARES TODAY Dear Fellow Pfizer Shareholder: On April 27, 2023, Pfizer will hold its Annual Meeting of Shareholders. We value your input as a holder of Pfizer common stock and encourage you to review our proxy materials and cast your vote today. You can view our proxy materials at https://investors.pfizer.com/proxy. For the reasons set forth in the 2023 Proxy Statement, the Board of Directors recommends that you vote: • "FOR" each director nominee; • "FOR" the ratification of the selection of KPMG LLP as the independent registered public accounting firm for 2023; • "FOR" the 2023 advisory approval of executive compensation; • In favor of "1 YEAR" for the frequency of future advisory votes on executive compensation; and • "AGAINST" the five shareholder proposals. For your convenience, a duplicate proxy/voting instruction card and return envelope are enclosed, along with telephone and Internet voting instructions. In the event that multiple proxies/voting instruction cards are received from you, the one with the latest date will be counted. The 2023 Annual Meeting will be held in a virtual meeting format only. Please view our proxy statement for additional details on how you can participate. Your vote is important and valued. I encourage you to vote in advance of the Annual Meeting by one of the methods described in the proxy materials and duplicate proxy/voting instruction card. Please act today to be sure your shares are voted. Sincerely, Margaret M. Madden Senior Vice President & Corporate Secretary Chief Governance Counsel Pfizer Inc. – Legal Division

------